Panel · Use case · Corporate Development
Asset Licensing Round Table.
LiveRound TableConvene business development, HEOR, regulatory and clinical operations on whether to license a late-stage asset.
Asset Licensing Round Table is a ready-made use case for Corporate Development. It ships under the Round Table template.
For corporate development leads. You get each discipline's view in its own terms, where they connect and disagree, what none covered and what the deliberation does not settle. Claims are cited or marked as gaps.
Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.
The decision
Should the company license a late-stage asset for a chronic inflammatory disease?
Who is at the table
A licensing decision rests on whether the asset will succeed in development and in the market. Historical success rates give a base rate, and the asset’s own data move the estimate from there.
| Seat | What it is asked | What it works from |
|---|---|---|
| Ecosystem Intelligence Orchestrator | Who else is interested, what the competing assets are, and what terms the market implies. | Public deal records and company disclosures. |
| HEOR Evidence Lead | Whether the asset’s profile will earn reimbursement against current treatments. | Comparator evidence and payer methods. |
| Regulatory Strategist | Whether the development path and the data to date support the intended label.2 | Agency guidance for the indication. |
| Clinical Operations Director | Whether the remaining trials are feasible on the timeline and budget.2 | Trial designs and enrollment feasibility. |
What the round table does
Start from a base rate. A published industry analysis of clinical development success rates gives the share of programs that move from one phase to the next. The panel uses it as a starting point and says how the asset differs from the average.1
The pivotal question is the estimand. The clinical seats check whether the trial question matches the claim the company wants to make, using the framework for estimands.2
Valuation is outside the report. The panel does not price the deal. It sets out the strengths and risks each discipline sees so that the deal team can price them.
Recommended length
Standard
Four disciplines bear on this question. Standard depth gives each a seat, with the table of connections and the dissent, in about four pages.
You can pick another length on the form. The other two stay available.
Assumptions the round table checks
The round table states the assumptions each seat relies on, and says what each gap limits. Examples for this question:
- The data room reflects the asset’s results to date.
- The competitive landscape will not change before launch.
- The licensor’s trial design will support the label the company wants.
Standards, guidance and sources
Frame
The decision practice behind the memo itself is on the template page.
What gets flagged
Any success rate not tied to the indication, any term not tied to a public deal, and any claim taken only from the licensor’s materials.
What arrives
- The question, and who was asked
- Where the panel lands
- What each discipline says
- Where the disciplines connect
- Where they disagree, and why it matters
- What none of them covered
- What changes, and what this does not cover
What it will not do
It is a deliberation of AI specialists and not a vote of human experts. It reports where they land and where they split, and the decision stays with you.
It does not value the asset or negotiate terms.
It is not a vote of human experts. Every seat is an AI specialist, and the report says so.
It does not add a seat that did not speak or invent a quote or a number.
It does not decide. It sets out the views, the dissent and the gaps for you to decide.
References
- [1] BIO, Informa Pharma Intelligence and QLS. Clinical Development Success Rates and Contributing Factors 2011–2020. February 2021. Known from search results and secondary reports; the figures were not read.
- [2] International Council for Harmonisation. Efficacy guidelines, including ICH E8(R1) and E9(R1). Not read.
Links checked 9 October 2026
These are the sources the template drew on. None of their authors or issuers has reviewed it.
About the Panel service
Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.
To edit a saved template, open New → Panel → From template, or the library rail on the service form.